Understanding Early-life Influenza Antibody Repertoire Imprinting Through Infection or Vaccination

了解生命早期流感抗体库通过感染或疫苗印记

基本信息

  • 批准号:
    10215742
  • 负责人:
  • 金额:
    $ 27.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-01 至 2021-07-31
  • 项目状态:
    已结题

项目摘要

Influenza is a persisting global threat, and the most pressing unmet need is to improve vaccination strategies to be more effective, with this fundamentally hinging on a better understanding of vaccinemediated immunity in humans. Due to the ubiquitous nature of influenza, people are exposed to influenza virus at an early age, resulting in the early development of antibody responses to the first encountered influenza strains. From this initial exposure to influenza via infection or vaccination, the initial influenza antibody repertoire is established, and it is constantly reshaped during one’s lifetime. Recent studies have suggested that this initial antibody repertoire generated from the first exposure is ‘imprinted’ in the immune system and exerts a major influence on the nature of the antibody response elicited upon subsequent challenges. Such imprinting sets the immune system on a path that bias immune responses to subsequent exposures to influenza, and there is an increasing understanding that early childhood imprinting might be the reason for the limited effectiveness of the annual flu vaccination. This study aims to characterize the immune response to influenza in young children and its effect on subsequent responses to influenza vaccination. The hypothesis is that that the first exposure through infection results in stronger imprinting of initial influenza antibody repertoire than the first exposure through vaccination. In Aim 1, the immune response to influenza vaccine in children who had documented prior natural infection or documented prior vaccination will be compared, focusing on the persistence of the antibodies from the first time point over 2 years of subsequent vaccinations. In Aim 2, the antibodies comprising the imprinted antibody repertoire will be functionally characterized to better understand the features of the imprinted antibodies. Collectively, this study will potentially elucidate the rules and mechanisms governing imprinting, which can be leveraged into the development of better vaccine immunogens as well as vaccination strategies.
流感是一个持续存在的全球威胁,最紧迫的未满足需求是改进疫苗接种

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jiwon Lee其他文献

Jiwon Lee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jiwon Lee', 18)}}的其他基金

Understanding the impact of imprinted serum antibody repertoire on subsequent vaccine responses
了解印迹血清抗体库对后续疫苗反应的影响
  • 批准号:
    10271749
  • 财政年份:
    2016
  • 资助金额:
    $ 27.42万
  • 项目类别:
Understanding the impact of imprinted serum antibody repertoire on subsequent vaccine responses
了解印迹血清抗体库对后续疫苗反应的影响
  • 批准号:
    10460275
  • 财政年份:
    2016
  • 资助金额:
    $ 27.42万
  • 项目类别:
Understanding the impact of imprinted serum antibody repertoire on subsequent vaccine responses
了解印迹血清抗体库对后续疫苗反应的影响
  • 批准号:
    10647708
  • 财政年份:
    2016
  • 资助金额:
    $ 27.42万
  • 项目类别:
Core C: IgSeq and NGS Core
核心 C:IgSeq 和 NGS 核心
  • 批准号:
    10549607
  • 财政年份:
    2011
  • 资助金额:
    $ 27.42万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 27.42万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 27.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了